Inycte weighs expansion options at Augustine Cut-Off headquarters site

Photo courtesy WHYY Newsworks
Photo courtesy WHYY Newsworks

Incyte, Inc. is studying expansion plans for its headquarters site on Augustine Cut-Off, just outside the city of Wilmington.

The company submitted preliminary plans to the New Castle County for an expansion to the headquarters at the former site of the Wanamaker  store, a longtime Wilmington landmark.

An opening ceremony for the headquarters was held in late 2014.

Michael Booth, vice president of investor relations, said “our plans and business expansion have led to rapid personnel growth, and we have added over 200 full-time positions over the past several years.”  That has left the headquarters building quickly being at capacity.

The jobs are “high-value, high-skill positions that attract applicants locally and from all over the U.S., and around the world,” Booth wrote in an email message.

The company, according to Booth, “wants its global HQ to remain in Wilmington.”

Booth stressed that a variety of options are being studied, “including the construction of a new building at 1801 Augustine Cut-Off. Click here for a look at filings with the county by Incyte and its engineering firm Duffield Associates, Pike Creek.

Booth went on to say that   “the current thinking involves adding space for approximately 400 additional Incyte associates. The plans submitted the county include a parking structure with  “green roof” plant cover.

The company employs more than 550 in Delaware.

Incyte was founded in California and later moved to Delaware, using  laboratories at the DuPont Experimental Station.

Former Incyte CEO  Paul Friedman, who  remains on the Incyte board of directors, was instrumental in moving the operation here.  Friedman is a former executive with DuPont’s pharmaceutical operations, which have since been sold.

Current CEO is  Hervé Hoppenot, former president of Novartis Oncology, an $11 billion business.

Incyte developed the blockbuster drug Jakafi, which is used to treat blood cancers and related disorders.  The company is now researching other uses for its discoveries and is partnering with other pharmaceutical companies. The publicly traded company’s stock is valued at $18.4 billion.

Click here for other DelawareBusinessDaily.con stories on Incyte.

The expansion has   partly offset job losses at AstraZeneca, which has restructured  its presence in Delaware.

A portion of its sprawling corporate  campus near Wilmington was sold to JPMorgan Chase, which plans to have a global technology hub and other operations at the site.

Facebook Comments